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POLICY PERSPECTIVE
eveN THOugH THe uSe OF 
SOMe pHARMACOTHeRApieS 
iN SubSTANCe uSe 
depeNdeNCe TReATMeNT iS 
ASSOCiATed WiTH pOSiTive 
TReATMeNT OuTCOMeS, 
publiCly FuNded 
NONpROFiT, gOveRNTMeNT 
OWNed, pRivATely FuNded 
NONpROFiT ANd FOR-pROFiT 
TReATMeNT CeNTeRS 
vARy iN THe AdOpTiON OF 
pHARMACOTHeRApiTeS FOR 
TReATiNg SubSTANCe uSe 
diSORdeRS. iN FACT, THe 
AdOpTiON OF MediCATiONS 
HAS beeN lOW ANd uNeveN 
ACROSS TReATMeNT 
AgeNCieS. 
Background
I
n the United States, the use of pharmacotherapies for treating substance use 
disorders is receiving increased attention. Evidence suggests that medications such 
as methadone and buprenorphine (also called agonist mediations) relate to positive 
outcomes in the treatment of opiate dependence, while naltrexone and disulfiram 
may improve outcomes when treating opiate dependence and cocaine dependence. 
Despite evidence of their effectiveness, the adoption of these therapies by treatment 
organizations has been slow. Research suggests that factors related to agencies’ 
organizational context can affect whether medications are offered to patients. 
An understanding of such factors is critical in bridging the “research to practice gap” 
in the use of pharmacotherapies for substance use disorder treatment.
In their study “The Adoption of Medications in Substance Abuse Treatment: 
Associations with Organizational Characteristics and Technology Clusters1,” Dr. 
Hannah K. Knudsen and colleagues examine the extent to which medications are used 
in the treatment protocols of 766 substance abuse treatment centers (from nationally 
representative samples of 363 publicly funded and 403 privately funded agencies). 
The authors also assess the relationship between organizational characteristics and the 
use of pharmacotherapies. In addition, they try to ascertain if there are patterns of 
association between medications.
Findings
The adoption of pharmacotherapies by agencies is low, and the likelihood  ■
of their availability differs by setting. Agonist medications were more likely to 
be offered by privately funded nonprofit centers and for-profit agencies than by 
publicly funded nonprofit centers. Similar findings were seen in the adoption of 
naltrexone. Government-owed facilities, privately funded nonprofits, and for-profit 
organizations were all more likely to prescribe disulfiram and selective serotonin 
reuptake inhibitors (SSRIs) than publicly funded nonprofit centers. Some of these 
differences are explained by other organizational characteristics.
Organizational characteristics play a part in the adoption of  ■
pharmacotherapies. Accredited programs were more likely to use agonists in 
treatment than non-accredited ones. Organizations affiliated with a hospital were 
more likely than freestanding centers to offer naltrexone, disulfiram, and SSRIs; 
in addition, mental health centers were more likely than freestanding centers to 
offer SSRIs. Programs that offer outpatient detoxification services were more likely 
than those not offering these services to adopt each of these three medications, 
while centers offering inpatient detoxification were more likely to have adopted 
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naltrexone and disulfiram than facilities without inpatient detoxification services. 
Centers offering residential treatment were less likely than nonresidential ones to 
offer agonists. Programs that employed physicians were more likely to adopt all 
four medications. 
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The availability of less-intensely regulated medications (naltrexone, disulfiram  ■
and SSRIs) shows a pattern of organizational characteristics that is different 
from agonist medications. The use of less-intensely regulated medications 
is linked to center type, affiliation, levels of care and staffing. That is, these 
medications are more likely to be used in government-owned and for-profit 
centers than publicly funded nonprofit centers, in hospital and mental health 
centers compared to freestanding centers, in centers providing detoxification 
services, and in centers with physicians and master’s level counselors on staff. 
As with less-intensely regulated medications, agonist medications are more likely 
to be available in centers with physicians on staff and in programs offering 
outpatient detoxification. In contrast to less-intensely regulated medications, 
agonist medications are more likely to be adopted by programs serving more 
opiate-dependent patients, by accredited centers, in larger facilities, and those 
centers that do not offer residential care. 
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